REGIONAL CHEMOTHERAPY

CURRENT CLINICAL ONCOLOGY

Maurie Markman, MD, SERIES EDITOR

Renal Cell Carcinoma: Molecular Biology, Immunology, and Clinical

Management, edited by RONALD M. BUKOWSKI AND ANDREW NOVICK, 2000

Current Controversies in Bone Marrow Transplantation, edited by BRIAN J. BOLWELL, 2000

Regional Chemotherapy: Clinical Research and Practice, edited by MAURIE MARKMAN, 2000

Intraoperative Irradiation: Techniques and Results, edited by L. L. GUNDERSON,

C. G. WILLETT, L. B. HARRISON, AND F. A. CALVO, 1999

REGIONAL CHEMOTHERAPY

Clinical Research and Practice

Edited by

MAURIE MARKMAN, MD

The Cleveland Clinic Foundation, Cleveland, OH

Springer Science+Business Media, LLC

© 2000 Springer Science+Business Media New York
Originally published by Humana Press Inc. in 2000
Softcover reprint of the hardcover 1st edition 2000

All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher.

All articles, comments, opinions, conclusions, or recommendations are those of the author(s), and do not necessarily reflect the views of the publisher.

This publication is printed on acid-free paper.
ANSI Z39.48-1984 (American National Standards Institute)
Permanence of Paper for Printed Library Materials.

Cover design by Patricia F. Cleary.

Photocopy Authorization Policy:

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Humana Press Inc., provided that the base fee of US \$10.00 per copy, plus US \$00.25 per page, is paid directly to the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Springer Science+Business Media, LLC. The fee code for users of the Transactional Reporting Service is: [0-89603-729-0/00 \$10.00 + \$00.25].

10 9 8 7 6 5 4 3 2 1

Library of Congress Cataloging-in-Publication Data

Main entry under title:

Current clinical oncology™.

Regional chemotherapy: clinical research and practice / edited by Maurie Markman.
p. cm.—(Current clinical oncology ; 2)
Includes bibliographical references and index.

ISBN 978-1-4684-9697-0 ISBN 978-1-59259-219-7 (eBook)
DOI 10.1007/978-1-59259-219-7

1. Cancer—Chemotherapy. 2. Infusion therapy. 3. Regional perfusion (Physiology). 4. Antineoplastic agents—Administration. I. Markman, Maurie. II. Series: Current clinical oncology (Totowa, N.J.) ; 2.
[DNLM: 1. Neoplasms—drug therapy. 2. Antineoplastic Agents—administration & dosage. 3. Perfusion, Regional. QZ 267 R3364 2000]
RC271.C5R42 2000
616.99'4061—dc21
DNLM/DLC
for Library of Congress

99-22882
CIP

PREFACE

Regional antineoplastic drug administration is not a new concept, having been examined since the earliest days of the modern chemotherapeutic era. For example, nitrogen mustard and hemisulfur mustard were administered by the intraperitoneal route in the 1950s as a strategy to treat malignant effusions (1,2), while during the same time period alkylating agents were delivered by direct intraarterial instillation to treat localized tumor masses (3).

Over the past several decades much has been learned regarding both the potential benefits (e.g., improvement in local symptoms and quality of life, prolongation of progression-free and overall survival) and the toxicities associated with regional antineoplastic drug delivery.

Local side effects of treatment include both the direct effects of the high concentrations of drug in contact with the infused/instilled body compartment [e.g., adhesion formation following intraperitoneal therapy (4), blindness following intra-carotid artery delivery (5), biliary sclerosis following intrahepatic artery infusions (6)] and the complications associated with the actual drug administration (e.g., infection of catheters and bleeding following intraarterial infusion).

In a number of specific malignant disease settings, this therapeutic strategy has become the “standard of care” in patient management. Examples include the use of intravesical therapy of localized bladder cancer (7), and intrathecal or intraventricular antineoplastic drug delivery for treatment of meningeal leukemia (8). In both situations regional therapy has been established as a highly effective treatment approach.

In other areas, such as the use of intraperitoneal chemotherapy in the management of ovarian cancer, accumulating data have strongly suggested an important role for the strategy in a subset of individuals with the malignancy. Two recently reported randomized clinical trials have demonstrated that, compared to the intravenous delivery of cisplatin, the intraperitoneal administration of the agent as initial chemotherapy of small volume residual disease results in an improvement in both progression-free and overall survival (9,10).

Finally, promising and highly innovative approaches to the management of malignant disease that employ regional drug delivery have been reported during the past several years from a number of major research centers throughout the world. These include the direct delivery of antineoplastic agents into body cavities (peritoneal cavity, pleura, pericardium, bladder, meninges) and arterial blood vessels, utilizing both cytotoxic and biological agents.

In *Regional Chemotherapy: Clinical Research and Practice* we have been extremely fortunate to assemble many leading clinicians and clinical investigators in the rapidly expanding arena of regional antineoplastic drug delivery from around the world, to contribute to a discussion of the current state-of-the-art, as well as new developments in this important area of oncologic care and research.

Although some of the approaches to be discussed remain highly experimental, it can reasonably be hoped and anticipated that many of these imaginative and innovative strategies will ultimately be recognized as “standard treatment” for patients with malignant disease confined to specific regions of the human body.

Maurie Markman, MD

References

1. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. *JAMA* 1955; **159**:1704–1707.
2. Green TH. Hemisulfur mustard in the palliation of patients with metastatic ovarian cancer. *Obstet Gynecol* 1959; **13**:383–393.

3. Sullivan RD, Jones R, Jr., Schnabel TG, et al. The treatment of human cancer with intra-arterial nitrogen mustard (methylbis(2-chloroethyl)amine hydrochloride) utilizing a simplified catheter technique. *Cancer* 1953; **6**:121–134.
4. Markman M, George M, Hakes T, et al. Phase 2 trial of intraperitoneal mitoxantrone in the management of refractory ovarian carcinoma. *J Clin Oncol* 1990; **8**:146–150.
5. DeWys WD, Fowler EH. Report of vasculitis and blindness after intracarotid injection of 1,3 bis(2-chloroethyl)-1-nitrosurea (BCNU), NSC-409962 in dogs. *Cancer Chemother Rep* 1973; **57**:33–40.
6. Hohn DS, Rayner AA, Economou JS, et al. Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. *Cancer* 1986; **57**:465–470.
7. Zincke H, Utz DC, Taylor WF, et al. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. *J Urol* 1983; **129**:505–509.
8. Bleyer WA. Intrathecal methotrexate versus central nervous system leukemia. *Cancer Drug Deliv* 1984; **1**:157–167.
9. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. *N Engl J Med* 1996; **335**:1950–1955.
10. Markman M, Bundy B, Benda J, et al. Randomized phase 3 study of intravenous (IV) cisplatin/paclitaxel versus moderately high dose IV carboplatin followed by IV paclitaxel and intraperitoneal cisplatin in optimal residual ovarian cancer: An Intergroup Trial (GOG, SWOG, ECOG). *Proc Am Soc Clin Oncol* 1998; **17**:361a.

CONTENTS

Preface	v
Contributors	ix
1 Principles of Regional Antineoplastic Drug Delivery	1
<i>Maurie Markman</i>	
2 Intrahepatic Chemotherapy for Metastatic Colorectal Cancer	5
<i>Nancy E. Kemeny and Omar T. Atiq</i>	
3 Regional Hepatic Arterial Infusion Chemotherapy for Hepatic Colorectal Metastases	21
<i>Robert J. Pelley</i>	
4 Regional Chemotherapy of Melanoma	33
<i>Mary S. Brady and Daniel G. Coit</i>	
5 Isolated Limb Perfusion for Malignant Melanoma and Soft Tissue Sarcoma	57
<i>Joseph M. Klausner, Dina Lev-Chelouche, Subhi Abu-Abeid, and Mordechai Gutman</i>	
6 Lung Perfusion for Treatment of Metastatic Sarcoma to the Lungs	87
<i>David Liu, Michael Burt, and Robert J. Ginsberg</i>	
7 Regional Chemotherapy of Cancer of the Pancreas	101
<i>James H. Muchmore and Jyoti Arya</i>	
8 National Cancer Institute Experience with Regional Therapy for Unresectable Primary and Metastatic Cancer of the Liver or Peritoneal Cavity	127
<i>H. Richard Alexander, David L. Bartlett, and Steven K. Libutti</i>	
9 Surgical Considerations in Intraperitoneal Chemotherapy	151
<i>Donald W. Wiper and Alexander W. Kennedy</i>	
10 Memorial Sloan-Kettering Cancer Center Experience with Intraperitoneal Chemotherapy of Ovarian Cancer	167
<i>Richard R. Barakat and David R. Spriggs</i>	
11 Southwest Oncology Group Experience with Intraperitoneal Chemotherapy of Ovarian Cancer	179
<i>David S. Alberts, Dava J. Garcia, Emily Fisher, and P. Y. Liu</i>	
12 Intraperitoneal Biologic Therapy for Ovarian Cancer	193
<i>John C. Elkas, Oliver Dorigo, and Jonathan S. Berek</i>	
13 Intraperitoneal Therapy with Fluoropyrimidines in the Treatment of Ovarian and Gastrointestinal Cancers	213
<i>Franco M. Muggia, Tamar Safra, Susan Jeffers, Agustin Garcia, and Susan Groshen</i>	
14 Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies	225
<i>Paul H. Sugarbaker</i>	
15 Memorial Sloan-Kettering Cancer Center Experience with Intraperitoneal Chemotherapy for Gastric Cancer	249
<i>Eileen O'Reilly and David P. Kelsen</i>	

16	Regional Therapy for Gastric Cancer with and without Peritoneal Metastasis by Intraperitoneal Hyperthermic Chemoperfusion	263
	<i>Shigeru Fujimoto and Makoto Takahashi</i>	
17	Intraperitoneal Chemotherapy in Management of Peritoneal Mesothelioma	285
	<i>Maurie Markman</i>	
18	Intravesical Therapy for Superficial Bladder Cancer	291
	<i>Kerry L. Kilbridge and Eric A. Klein</i>	
19	Principles of Intrathecal Chemotherapy	305
	<i>Glen Stevens and David M. Peereboom</i>	
20	Regional Chemotherapy for Meningeal Involvement with Breast Cancer	319
	<i>Beth A. Overmoyer</i>	
21	Regional Chemotherapy for Treatment and Prophylaxis of Meningeal Lymphoma.....	331
	<i>Brad Pohlman</i>	
22	Regional Chemotherapy for the Treatment and Prophylaxis of Meningeal Leukemia	339
	<i>Matt E. Kalaycio</i>	
	Index	357

CONTRIBUTORS

- SUBHI ABU-ABEID, MD, *Department of Surgery, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel*
- DAVID S. ALBERTS, MD, *Section of Hematology and Oncology, Department of Medicine and Pharmacology, Arizona Cancer Center, University of Arizona, Tucson, AZ*
- H. RICHARD ALEXANDER, MD, *Head, Surgical Metabolism Section, Surgery Branch, National Cancer Institute/NIH, Bethesda, MD*
- JYOTI ARYA, MD, *Department of Surgery, Tulane University School of Medicine, New Orleans, LA*
- OMAR T. ATIQ, MD, *Associate Clinical Professor of Medicine, University of Arkansas for Medical Sciences, and Medical Director, Cancer treatment Program, Jefferson Medical Center, Pine Bluffs, AR*
- RICHARD R. BARAKAT, MD, *Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY*
- DAVID L. BARTLETT, MD, *Surgical Metabolism Section, Surgery Branch, National Cancer Institute/NIH, Bethesda, MD*
- JONATHAN S. BEREK, MD, *Vice Chairman, Department of Obstetrics and Gynecology, UCLA School of Medicine, Los Angeles, CA*
- MARY S. BRADY, MD, *Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY*
- MICHAEL BURT, MD, PhD, *Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY*
- DANIEL G. COIT, MD, *Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY*
- OLIVER DORIGO, MD, *UCLA Women's Gynecologic Oncology Center, Department of Obstetrics and Gynecology, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, CA*
- JOHN C. ELKAS, MD, *UCLA Women's Gynecologic Oncology Center, Department of Obstetrics and Gynecology, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, CA*
- EMILY FISHER, MS, *Southwest Oncology Group Statistical Center, Seattle, WA*
- SHIGERU FUJIMOTO, MD, *Director, Social Insurance, Funabashi Central Hospital, Funabashi, Japan*
- AGUSTIN GARCIA, MD, *Kaplan Comprehensive Cancer Center, New York University Medical Center, New York, NY*
- DAVA J. GARCIA, BA, *Arizona Cancer Center, Tucson, AZ*
- ROBERT J. GINSBERG, MD, *Chief of Thoracic Surgery, William G. Caban Chair of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY*
- SUSAN GROSHEN, PhD, *Kaplan Comprehensive Cancer Center, New York University Medical Center, New York, NY*
- MORDECHAI GUTMAN, MD, *Department of Surgery, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel*
- SUSAN JEFFERS, RN, *Kaplan Comprehensive Cancer Center, New York University Medical Center, New York, NY*
- MATT E. KALAYCIO, MD, *Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH*

- DAVID P. KELSEN, *Chief, Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY*
- NANCY E. KEMENY, MD, *Professor of Medicine, Cornell University Medical College, and Attending Physician and Member, Memorial Sloan-Kettering Cancer Center, New York, NY*
- ALEXANDER W. KENNEDY, MD, *Department of Gynecology, The Cleveland Clinic Foundation, Cleveland, OH*
- KERRY L. KILBRIDGE, MD, *Division of Hematology–Oncology, University of Virginia, Charlottesville, VA*
- JOSEPH M. KLAUSNER, MD, *Professor and Head of Surgery, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel*
- ERIC A. KLEIN, MD, *Head, Section of Urologic Oncology, Department of Urology, The Cleveland Clinic Foundation, Cleveland, OH*
- DINA LEV-CHELOUCHE, MD, *Department of Surgery, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel*
- STEVEN K. LIBUTTI, MD, *Surgical Metabolism Section, Surgery Branch, National Cancer Institute/NIH, Bethesda, MD*
- DAVID LIU, MD, *Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY*
- P. Y. LIU, PhD, *Southwest Oncology Group Statistical Center, Seattle, WA*
- MAURIE MARKMAN, MD, *Director, The Cleveland Clinic Taussig Cancer Center, and Chairman, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH*
- JAMES H. MUCHMORE, MD, *Associate Professor of Surgery, Department of Surgery, Tulane University School of Medicine, New Orleans, LA*
- FRANCO M. MUGGIA, MD, *Division of Oncology, Kaplan Comprehensive Cancer Center, New York University Medical Center, New York, NY*
- EILEEN M. O'REILLY, MD, *Clinical Assistant Attending Physician, MSKCC Instructor in Medicine, Cornell University Medical Center, New York, NY*
- BETH A. OVERMOYER, MD, *Ireland Cancer Center, University Hospitals of Cleveland, Cleveland, OH*
- ROBERT J. PELLE, MD, *Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH*
- DAVID M. PEERBOOM, MD, *Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH*
- BRAD A. POHLMAN, MD, *Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH*
- TAMAR SAFRA, MD, *Kaplan Comprehensive Cancer Center, New York University Medical Center, New York, NY*
- DAVID R. SPRIGGS, MD, *Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY*
- GLEN STEVENS, PhD, DO, *The Cleveland Clinic Foundation, Cleveland, OH*
- PAUL H. SUGARBAKER, MD, *Washington Cancer Institute, Washington Hospital Center, Washington, DC*
- MAKOTO TAKAHASHI, MD, *Social Insurance, Funabashi Central Hospital, Funabashi, Japan*
- DONALD W. WIPER, MD, *Department of Gynecology, The Cleveland Clinic Foundation, Cleveland, OH*